Stockholders overwhelmingly approved liquidation and dissolution of the Company at the June 5, 2025 Annual Meeting Initial distribution currently expected in the range between approximately $5.30 and $5.35 per share of common stock, expected in the third quarter of 2025 THB335 demonstrated 85% serum tryptase reduction with an encouraging safety profile in an additional Phase 1 cohort evaluating 100mg dose with new drug product capsule formulation Company initiating a sale process of THB335 SAN FRANCISCO, J ...

Financial Performance - The company reported a net loss of $15.8 million for the three months ended March 31, 2025, representing a 102% increase compared to a net loss of $7.9 million for the same period in 2024[110]. - Total operating expenses increased by 66% to $18.7 million in Q1 2025, up from $11.3 million in Q1 2024, driven by a 71% increase in research and development expenses[110]. - The company has an accumulated deficit of approximately $175.5 million as of March 31, 2025[99]. - Net cash used in operating activities increased from $6.3 million in Q1 2024 to $13.5 million in Q1 2025, primarily due to a net loss of $15.8 million in 2025[120]. Cash and Liquidity - As of March 31, 2025, the company had $271.6 million in cash and cash equivalents, expected to fund operations through at least 2026[106]. - The company expects existing cash and cash equivalents to fund operations through at least 2026, although this estimate is based on assumptions that may prove incorrect[124]. - As of March 31, 2025, the company had cash and cash equivalents totaling $271.6 million, primarily in money market funds and U.S. Treasury-backed securities[138]. Research and Development - The company plans to complete Phase 2 readiness activities for THB335 by mid-2025 to maximize the value of the program for potential sale[93]. - Research and development expenses increased by $4.4 million, from $6.2 million for the three months ended March 31, 2024, to $10.6 million for the same period in 2025, representing a 71% increase[112]. - The increase in research and development expenses was primarily due to higher direct costs related to the THB335 program and increased indirect employee-related costs[112]. - The company has halted all non-THB335-related research and reduced its workforce by approximately 50% as part of a restructuring effort[92]. Strategic Initiatives - The company intends to seek stockholder approval for a Plan of Liquidation and Dissolution at the annual meeting on June 5, 2025[94]. - The company has entered into a license agreement with Novartis, which includes potential milestone payments totaling up to $231.7 million and tiered royalties on net sales of licensed products[108]. Market and Economic Conditions - The company qualifies as a "smaller reporting company" with a market value of stock held by non-affiliates less than $700 million and annual revenue below $100 million[135]. - The company is exposed to interest rate risk, as cash equivalents are sensitive to changes in U.S. interest rates, which could affect interest income[139]. - The company currently does not face significant foreign currency exchange risk, as all operations and expenses are in U.S. dollars, but future contracts with non-U.S. vendors may introduce some risk[140]. - Inflation has not materially impacted the company's financial position to date, but rising inflation rates could increase labor and clinical trial costs in the near future[141]. Other Financial Metrics - Total other income, net decreased by $0.6 million, from $3.4 million in Q1 2024 to $2.9 million in Q1 2025, mainly due to fluctuations in interest rates affecting interest income[114]. - General and administrative expenses rose by $3.0 million, from $5.1 million in Q1 2024 to $8.1 million in Q1 2025, driven by personnel-related expenses and stock-based compensation[113]. - The company filed a shelf registration statement allowing for the offering of up to $400.0 million in various securities, including common stock and debt securities[116]. - During the year ended December 31, 2024, the company sold 3,900,000 shares through its ATM Facility, generating gross proceeds of approximately $49.9 million[117]. - The company may incur contingent royalty payments under the Novartis Agreement, with royalty percentages in the mid-single digits of sales, but has not paid any royalties to date[128].

Financial Position - As of March 31, 2025, the company's preliminary unaudited cash, cash equivalents, and restricted cash amount to approximately $272 million[5]. Liquidation and Dissolution - The board of directors unanimously approved the liquidation and dissolution of the company on April 10, 2025[7]. - The company plans to hold its annual meeting on June 5, 2025, to seek stockholder approval for the liquidation and dissolution[8]. - The board reserves the right to abandon the proposed liquidation and dissolution if deemed not in the best interests of the company and its stockholders[8]. - The company intends to file a proxy statement and other relevant materials with the SEC regarding the planned dissolution[10]. Strategic Alternatives - The company is evaluating strategic alternatives to maximize stockholder value, including potential acquisitions or mergers[7]. Risks and Uncertainties - Forward-looking statements regarding the dissolution process involve substantial risks and uncertainties[12]. - The company may face potential tax claims and litigation matters that could impact the dissolution process[13]. - The adequacy of reserves to satisfy obligations during the dissolution is uncertain and subject to change[13]. - The company has not conducted an exhaustive inquiry into all relevant information regarding the dissolution[13].

Board of Directors has approved plan to liquidate and intends to seek stockholder approval for dissolution of the Company at the Annual Meeting of Stockholders on June 5, 2025 Initial distribution expected in the range between approximately $246.6 million and $255.4 million, or approximately $5.13 and $5.33 per share of common stock, expected in the third quarter of 2025 Sale of the Company’s assets, including THB335, to be initiated pending stockholder approval of the Plan of Liquidation and Dissolution S ...

Financial Performance - As of December 31, 2024, Third Harmonic Bio reported cash and cash equivalents of $285.1 million, an increase from $269.1 million in 2023[6][15]. - The net loss for Q4 2024 was $13.1 million, compared to a net loss of $6.8 million in Q4 2023, with the annual net loss increasing to $45.5 million from $30.8 million in 2023[10][17]. - Total operating expenses for the year ended December 31, 2024, were $58.9 million, up from $44.0 million in 2023[17]. - The weighted-average common stock outstanding increased from 39.6 million in 2023 to 41.7 million in 2024[17]. Research and Development - Research and development (R&D) expenses for Q4 2024 were $10.5 million, up from $5.9 million in Q4 2023, and total R&D expenses for the year increased to $36.5 million from $24.0 million in 2023[8][17]. - Third Harmonic Bio plans to initiate a 12-week, placebo-controlled Phase 2 study for THB335 in chronic spontaneous urticaria by mid-2025[3]. - The company has halted all non-THB335 related research and reduced its workforce by approximately 50%[5]. Strategic Initiatives - Third Harmonic Bio is exploring strategic alternatives to maximize shareholder value through potential transactions or business combinations[4]. - The company estimates cash and cash equivalents will range from approximately $262 million to $267 million by June 30, 2025[7][6]. General and Administrative Expenses - General and administrative (G&A) expenses for Q4 2024 rose to $5.9 million from $4.5 million in Q4 2023, with total G&A expenses for the year increasing to $22.4 million from $20.0 million in 2023[9][17].

Recently presented THB335 Phase 1 data support advancement into Phase 2 clinical trial in chronic spontaneous urticaria (CSU) Strategic alternatives process underway to maximize value creation across all assets in the company Strong financial position with cash and cash equivalents totaling $285.1 million as of December 31, 2024 SAN FRANCISCO, March 27, 2025 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammator ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM ____________________ TO ____________________ Commission File Number 001-41498 THIRD HARMONIC BIO, INC. (Exact name of Registrant as specified in its Charter) | Del ...

Group 1 - The stock of Third Harmonic Bio, Inc. (THRD) has experienced a significant decline of 31.6% over the past four weeks due to excessive selling pressure, but it is now in oversold territory, indicating a potential for a turnaround [1] - The Relative Strength Index (RSI) is a key technical indicator used to determine if a stock is oversold, with a reading below 30 typically indicating this condition [2] - THRD's current RSI reading is 26.95, suggesting that the heavy selling may be exhausting itself and a trend reversal could be imminent [5] Group 2 - There is a strong consensus among sell-side analysts regarding THRD's ability to report better earnings than previously predicted, with a 25.2% increase in the consensus EPS estimate over the last 30 days [6] - The upward trend in earnings estimate revisions is generally associated with price appreciation in the near term, indicating a positive outlook for THRD [6] - THRD holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate trends and EPS surprises, further supporting the potential for a turnaround [7]

Core Viewpoint - Third Harmonic Bio, Inc. (THRD) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook based on rising earnings estimates, which significantly influence stock prices [1][3]. Earnings Estimates and Stock Performance - The Zacks rating system emphasizes the correlation between changes in earnings estimates and stock price movements, suggesting that revisions in earnings estimates are a powerful indicator of future stock performance [4][6]. - For Third Harmonic Bio, the Zacks Consensus Estimate has increased by 25.2% over the past three months, reflecting a positive trend in earnings outlook [8]. Company Financials - The company is projected to earn -$1.08 per share for the fiscal year ending December 2024, which represents a year-over-year decline of 38.5% [8]. Investment Implications - The upgrade to Zacks Rank 2 positions Third Harmonic Bio in the top 20% of Zacks-covered stocks, suggesting a strong potential for market-beating returns in the near term [10].

Core Viewpoint - Third Harmonic Bio, Inc. (THRD) has experienced a significant decline of 39.6% in its stock price over the past four weeks, but it is now in oversold territory, suggesting a potential turnaround due to improved earnings expectations from analysts [1]. Group 1: Stock Performance and Technical Indicators - The stock is currently in oversold territory with a Relative Strength Index (RSI) reading of 15.51, indicating that the heavy selling pressure may be exhausting itself [5]. - A stock is generally considered oversold when its RSI falls below 30, which helps investors identify potential entry points for a rebound [2][3]. Group 2: Earnings Estimates and Analyst Consensus - There has been a strong consensus among sell-side analysts to raise earnings estimates for THRD, resulting in a 25.2% increase in the consensus EPS estimate over the last 30 days [5]. - An upward trend in earnings estimate revisions typically correlates with price appreciation in the near term, indicating a potential recovery for THRD [5]. Group 3: Zacks Rank and Investment Potential - THRD currently holds a Zacks Rank of 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, further supporting the potential for a turnaround [6].